Sign in to view content

Wet AMD 5 Symposium

Video
Published 2020

Related

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated With Intravitreal Aflibercept or Ranibizumab in the VIEW studies
Robert L. Avery, MD
On Demand Cases, Courses, and Papers
2017

Category: AMD-Neovascular

See more

Annual Meeting Talks